Status:
COMPLETED
Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)
Lead Sponsor:
Kocaeli University
Conditions:
Carbapenem Resistant Bacterial Infection
Eligibility:
All Genders
18+ years
Brief Summary
Using our own patient data, our study aimed to predict mortality that can develop in Carbapenem-resistant Gram-negative bacilli bloodstream infections with a machine learning-based model. In the inte...
Detailed Description
Carbapenems are one of the last-resort antibiotics used to treat severe infections caused by multi-drug resistant Gram-negative pathogens. Infections with Carbapenem-resistant Gram-negative bacilli (C...
Eligibility Criteria
Inclusion
- In our study, patients who were monitored in our hospital's tertiary Intensive Care Unit between June 2017 and June 2023 and developed bloodstream infections with Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa will be retrospectively included.
Exclusion
- Patients under the age of 18 and those with infections other than bloodstream infections will not be included.
Key Trial Info
Start Date :
April 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 28 2025
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT06167083
Start Date
April 12 2024
End Date
June 28 2025
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kocaeli University
Kocaeli, Turkey (Türkiye)